ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,581 to 4,600 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Sexual Health-PRO vs Post Visit (Fidelity) Survey: PrEP Prescriptions11 of 1,135

0 of 242

1.0 points

-0.7 to 1.7

1,377NCT07209722

PrEP4Her: Developing a Novel Strategy to Implement PrEP Into Women's Healthcare

Selenium vs Placebo: deaths from any cause11 of 685

10 of 689

0.2 points

-1.2 to 1.6

1,374NCT00078897

Selenium for Prevention of Adenomatous Colorectal Polyps

Selenium vs Placebo: serious adverse events228 of 685

226 of 689

0.5 points

-4.5 to 5.4

1,374NCT00078897

Selenium for Prevention of Adenomatous Colorectal Polyps

Group 1: Menactra and Routine Pediatric Vaccines vs Group 2: Routine Pediatric Vaccines: serious adverse events42 of 1,053

5 of 321

2.4 points

0.2 to 4.1

1,374NCT00483574

Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers

Telmisartan 40mg and Amlodipine 5mg vs Telmisartan 80mg and Amlodipine 5mg: serious adverse events22 of 976

6 of 397

0.7 points

-1.2 to 2.1

1,373NCT00614380

Open Label Study Telmisartan and Amlodipine in Hypertension

Naïve to Botox® Treatment vs Non-naïve to Botox® Treatment: serious adverse events5 of 506

33 of 866

-2.8 points

-4.4 to -1.1

1,372NCT00535938

MDs on Botox Utility (MOBILITY)

TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in The Safety Population176 of 685

176 of 687

0.1 points

-4.5 to 4.7

1,372NCT03788967

Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

TBPM-PI-HBr 600 mg vs Ertapenem 1 g: serious adverse events14 of 685

12 of 687

0.3 points

-1.2 to 1.8

1,372NCT03788967

Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

Subcutaneous Abatacept vs Intravenous Abatacept: Double-blind Period: Number of Participants Achieving American College of Rheumatology (ACR) 20 Response at Day 169527 of 693

514 of 678

0.2 points

-4.3 to 4.8

1,371NCT00559585

Methotrexate-Inadequate Response Study

BCG-vaccine vs Control Children: Specific IgE55 of 743

50 of 627

-0.6 points

-3.5 to 2.2

1,370NCT01694108

Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children.

Indomethacin vs Glycerin: the Incidence of Post-ESWL Pancreatitis60 of 685

84 of 685

-3.5 points

-6.8 to -0.2

1,370NCT02797067

Rectal Indomethacin to Prevent Post ESWL-pancreatitis

Restrictive vs Liberal: A Composite Endpoint of All-cause Post-randomization Mortality, Myocardial Infarction (MI), Coronary Revascularization, Acute Renal Failure, or Post-randomization Ischemic Stroke up to 90 Days After Randomization71 of 700

61 of 670

1.0 points

-2.1 to 4.2

1,370NCT03229941

Transfusion Trigger After Operations in High Cardiac Risk Patients

CHICA Type 2 Diabetes Module vs Usual Care: Number of Children With Documented Risk Factors for Type 2 Diabetes283 of 685

282 of 684

0.1 points

-5.1 to 5.3

1,369NCT01814787

Computer Automation for Diagnosis and Management of Childhood Type 2 Diabetes

Restrictive vs Liberal: All-cause Mortality at 1 Year After Randomization105 of 701

94 of 668

0.9 points

-2.8 to 4.6

1,369NCT03229941

Transfusion Trigger After Operations in High Cardiac Risk Patients

Restrictive vs Liberal: deaths from any cause105 of 701

94 of 668

0.9 points

-2.8 to 4.6

1,369NCT03229941

Transfusion Trigger After Operations in High Cardiac Risk Patients

LY2605541 + Insulin Lispro vs Insulin Glargine + Insulin Lispro: serious adverse events79 of 691

63 of 677

2.1 points

-1.1 to 5.4

1,368NCT01468987

A Study in Participants With Type 2 Diabetes Mellitus

Alogliptin + Thiazolidinedione vs Alogliptin + Other: serious adverse events3 of 1,248

0 of 120

0.2 points

-2.9 to 0.7

1,368NCT01945242

Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Combination Therapy With Thiazolidinediones"

Teriparatide vs Risedronate: serious adverse events138 of 683

117 of 683

3.1 points

-1.1 to 7.2

1,366NCT01709110

VERtebral Fracture Treatment Comparisons in Osteoporotic Women

BE1116 vs Placebo: deaths from any cause146 of 689

114 of 677

4.4 points

0.2 to 8.5

1,366NCT05568888

Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )

Intervention vs Control: serious adverse events7 of 683

3 of 682

0.6 points

-0.4 to 1.7

1,365NCT00667368

Bacterial Vaginosis Home Screening to Prevent STDs

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=230"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=230

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT07209722-0939329c",
        "title": "Sexual Health-PRO vs Post Visit (Fidelity) Survey: PrEP Prescriptions",
        "summary": "11 of 1135 against 0 of 242; risk difference 1.0 points, 95% interval -0.7 to 1.7; NCT07209722, PrEP4Her: Developing a Novel Strategy to Implement PrEP Into Women's Healthcare",
        "record": "/library/comparisons/NCT07209722-0939329c",
        "nct_id": "NCT07209722",
        "kind": "outcome",
        "participants": 1377,
        "risk_difference": {
          "value": 0.009691629955947136,
          "lower": -0.0065074332379784095,
          "upper": 0.017270837089201376
        },
        "group_1": "11 of 1,135",
        "group_2": "0 of 242",
        "difference": "1.0 points",
        "interval": "-0.7 to 1.7",
        "trial_title": "PrEP4Her: Developing a Novel Strategy to Implement PrEP Into Women's Healthcare"
      },
      {
        "id": "NCT00078897-deaths",
        "title": "Selenium vs Placebo: deaths from any cause",
        "summary": "11 of 685 against 10 of 689; risk difference 0.2 points, 95% interval -1.2 to 1.6; NCT00078897, Selenium for Prevention of Adenomatous Colorectal Polyps",
        "record": "/library/comparisons/NCT00078897-deaths",
        "nct_id": "NCT00078897",
        "kind": "deaths",
        "participants": 1374,
        "risk_difference": {
          "value": 0.0015446060618901827,
          "lower": -0.012378097588588337,
          "upper": 0.01565530519348074
        },
        "group_1": "11 of 685",
        "group_2": "10 of 689",
        "difference": "0.2 points",
        "interval": "-1.2 to 1.6",
        "trial_title": "Selenium for Prevention of Adenomatous Colorectal Polyps"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=231",
  "request_id": "gZLrkcg4zAJf4k7W"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

Cell lines

Cellosaurus

One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.

Journal index

PubMed and NLM's journal list

One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?